Is AstraZeneca (AZN) a Reliable Dividend Stock for Long-Term Investors?

AstraZeneca PLC (NASDAQ:AZN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025.

Is AstraZeneca (AZN) a Reliable Dividend Stock for Long-Term Investors?

A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases.

AstraZeneca PLC (NASDAQ:AZN) has a strong lineup of drugs in development, which should help it navigate upcoming patent expirations. By the end of the first quarter, it had secured around 13 drug approvals or label updates. Among its most promising experimental treatments are two potential weight management drugs, AZD5004 and AZD6234. Overall, the company is working on nearly 200 programs in its research pipeline.

In the first quarter of 2025, AstraZeneca PLC (NASDAQ:AZN) reported revenue of $13.6 billion, which showed a 7% growth from the same period last year. Total revenue has grown across all key regions, with core operating profit rising by 12%. The company is also planning to ramp up its investment in manufacturing and research in the U.S., building on its major R&D centers in Gaithersburg, Maryland, and Cambridge, Massachusetts. Overall, it is steadily moving closer to its goal of reaching $80 billion in total revenue by 2030.

AstraZeneca PLC (NASDAQ:AZN) currently pays an interim dividend of $1.03 per share and has a dividend yield of 2.25%, as of July 17. It is one of the best dividend stocks in the pharma sector as the company has been paying regular dividends to shareholders for the past 32 years.

While we acknowledge the potential of AZN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AZN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Best Industrial Dividend Stocks to Buy Right Now and 10 Best Passive Income Stocks to Buy Now.

Disclosure: None.